I disagree with jonesingPan on the interests of big pharma. The more PAB moves ahead under its' own funds the closer it gets to a marketable product . Should PAB progress satisfactorily to and through stage 1 trials it's all over for big pharma to buy at less than many billions. I've been with PAB virtually since its' listing and have a friend or 2 in this biomed science who speak highly of the successes of PAB and who express confidence in their product. To those who continually naysay why not just leave, hopefully at a very low sp.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.731M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $3.509K | 1.754M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 46 | 104890723 | 0.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.2¢ | 54489518 | 26 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| PAB (ASX) Chart |